EGFR and cancer: Similarly, the pyruvate dehydrogenase kinase 1 (PDK1) inhibitor Cpd64, when combined with EGFR TKI, improved anti-cancer effects in EGFR-mutant NCI-H1975 and NCI-H1650 cell lines and in a xenograft mouse model via the improvement of oxidative phosphorylation and mitochondrial respiration (Wang F. et al., 2021).